Skip to main content
The Long Run with Luke Timmerman

Ep214: Shana Kelley on a Wearable Continuous Immune Monitor

47 min episode · 2 min read
·
Shana Kelley

Episode

47 min

Read time

2 min

Topics

Productivity, Relationships, Startups

AI-Generated Summary

Key Takeaways

  • ✓Active Reset Mechanism: The core technical breakthrough enabling continuous protein sensing uses oscillating electric fields to physically dislodge bound proteins from electrode surfaces, resetting sensors back to baseline. Without this, standard affinity-based sensors remain locked to proteins for roughly 24 hours, making real-time fluctuation tracking impossible. This "active reset" approach is now being adapted by other research groups using constant-field variations.
  • ✓Interstitial Fluid Targeting: The device uses a single microneedle embedded just beneath the skin to sample interstitial fluid rather than blood, deliberately mirroring the continuous glucose monitor form factor. Smaller cytokine proteins equilibrate rapidly from blood into interstitial fluid, making them detectable at measurable concentrations without invasive blood draws, which also reduces infection risk and improves patient tolerance.
  • ✓Commercialization Sequencing: Based on prior startup experience, Kelley identifies a clear sequencing requirement: academic labs must build an FDA-grade prototype before larger industrial partners will engage seriously. Early-stage hardware integration — electrical engineering, microfabrication, industrial design, sensor chemistry — is too granular for large companies, making an initial startup vehicle the practical commercialization path before any acquisition or licensing deal.
  • ✓Inflammation as a Universal Clinical Signal: A review co-authored with cardiologists, neurologists, and critical care specialists identified continuous inflammatory monitoring as actionable across multiple disease areas. Heart failure patients who cycle repeatedly through hospitalization represent one near-term target, where real-time cytokine panels could enable precise medication titration and intervention timing rather than reactive crisis management after symptoms escalate.
  • ✓Molecular Dynamic Simulation as a Design Tool: Partnering with a Northwestern computational chemistry group to run molecular dynamic simulations of electrode-surface sensors transformed sensor development from empirical trial-and-error into a controllable design process. Visualizing exactly how sensors behave at the electrode surface revealed previously hidden mechanisms, producing multiple "unlock moments" that accelerated optimization of sensor architecture and performance.

What It Covers

Northwestern University professor Shana Kelley describes her team's development of a continuous wearable immune monitor, modeled after continuous glucose monitors, that tracks inflammatory protein levels in real time. Mouse trials published in Science in December 2024 demonstrated proof of concept, with human clinical trials and commercialization partnerships now in active pursuit.

Key Questions Answered

  • •Active Reset Mechanism: The core technical breakthrough enabling continuous protein sensing uses oscillating electric fields to physically dislodge bound proteins from electrode surfaces, resetting sensors back to baseline. Without this, standard affinity-based sensors remain locked to proteins for roughly 24 hours, making real-time fluctuation tracking impossible. This "active reset" approach is now being adapted by other research groups using constant-field variations.
  • •Interstitial Fluid Targeting: The device uses a single microneedle embedded just beneath the skin to sample interstitial fluid rather than blood, deliberately mirroring the continuous glucose monitor form factor. Smaller cytokine proteins equilibrate rapidly from blood into interstitial fluid, making them detectable at measurable concentrations without invasive blood draws, which also reduces infection risk and improves patient tolerance.
  • •Commercialization Sequencing: Based on prior startup experience, Kelley identifies a clear sequencing requirement: academic labs must build an FDA-grade prototype before larger industrial partners will engage seriously. Early-stage hardware integration — electrical engineering, microfabrication, industrial design, sensor chemistry — is too granular for large companies, making an initial startup vehicle the practical commercialization path before any acquisition or licensing deal.
  • •Inflammation as a Universal Clinical Signal: A review co-authored with cardiologists, neurologists, and critical care specialists identified continuous inflammatory monitoring as actionable across multiple disease areas. Heart failure patients who cycle repeatedly through hospitalization represent one near-term target, where real-time cytokine panels could enable precise medication titration and intervention timing rather than reactive crisis management after symptoms escalate.
  • •Molecular Dynamic Simulation as a Design Tool: Partnering with a Northwestern computational chemistry group to run molecular dynamic simulations of electrode-surface sensors transformed sensor development from empirical trial-and-error into a controllable design process. Visualizing exactly how sensors behave at the electrode surface revealed previously hidden mechanisms, producing multiple "unlock moments" that accelerated optimization of sensor architecture and performance.

Notable Moment

Kelley describes implanting sensors in diabetic rats and detecting a brief, transient cytokine spike caused solely by the needle insertion itself — a minute-level inflammatory signal that vanished quickly. This incidental finding illustrated the resolution the device achieves, capturing immune responses invisible to any existing clinical measurement tool.

Know someone who'd find this useful?

Episode Transcript

Welcome to the Long Run. This is a podcast for biotech adventurers. I'm your host, Luke Timmerman. Today's guest is Shana Kelley. Shana is a professor of chemistry at Northwestern University and the president of the Chan Zuckerberg Biohub in Chicago. One of the cool projects she oversees is for a continuous wearable immune monitor. It's inspired by continuous glucose monitors that have changed the way diabetes is treated and managed. No such device exists today for the continuous tracking of inflammation. But if her team of chemists, biologists, and engineers can pull this off, it would have big implications for research and treatment of immune disorders that affect millions of more people. The detection of inflammatory proteins was demonstrated in mice and published in Science in December 2024. You can find a link to that research article in the show summary on timmermanreport.com. The next steps to build something suitable for the marketplace will require some kind of industry partnership. Shaina, like a lot of scientists, has taken a circuitous path. I enjoyed hearing her story of how she got to this moment of possibility to seize on new technology tools and growing knowledge of biology to spearhead a project with this much potential for human health. Now before we get started, a word from the sponsor of the show, AlphaSense. Anyone who's tried to stay current on a fast moving therapeutic area knows the real problem isn't finding information. It's that there's too much of it, and it changes every week. Alfasense just launched SuperAnalyst, an always on agent that works like a power user inside the platform on your behalf. It draws on Alfasense's full life sciences content universe: clinical trial data, peer reviewed literature, regulatory filings, conference presentations, and expert transcripts with researchers, clinicians, and executives. And it keeps monitoring your space even after you've closed your laptop. It's designed to act like an extension of your research team. It remembers the programs and competitors you're tracking, follows your process, and applies it automatically to new data as it comes in. And every output links back to its original source, so when you're citing a trial result, you can see exactly where the number came from. Take the task you've been meaning to get to, tracking a competitor's trial program or flagging the next regulatory decision before it hits, and hand it to SuperAnalyst. Start your free trial at alphasense.comthelongrun. All one word. That's alpha-sense.com/thelongrun. And quick question. When was the last time a CRO told you what something costs before you sign an NDA, sat through two scoping calls, and waited a week for a scope of work? In bioanalysis, pricing gets treated like a closely guarded secret. DashBio thinks that's backward. It publishes pricing publicly on its website and even has a calculator that shows how the price changes if you redesign your study. You can see what your study costs before you talk to a human being. No surprise line items. No it …

Get the full transcript (7,484 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all The Long Run with Luke Timmerman transcripts →

You just read a 3-minute summary of a 44-minute episode.

Get The Long Run with Luke Timmerman summarized like this every Monday — plus up to 2 more podcasts, free.

Pick Your Podcasts — Free

Keep Reading

More from The Long Run with Luke Timmerman

We summarize every new episode. Want them in your inbox?

Similar Episodes

Related episodes from other podcasts

Explore Related Topics

This podcast is featured in Best Biotech Podcasts (2026) — ranked and reviewed with AI summaries.

Read this week's Startups & Product Podcast Insights — cross-podcast analysis updated weekly.

You're clearly into The Long Run with Luke Timmerman.

Every Monday, we deliver AI summaries of the latest episodes from The Long Run with Luke Timmerman and 192+ other podcasts. Free for one show.

Start My Monday Digest

No credit card · Unsubscribe anytime